KRAS and ovarian serous carcinoma: In low-grade ovarian serous carcinomas, estimated 27% to 54% of cases harbor mutations in KRAS oncogene, whereas in high-grade serous carcinomas, mutation rate of KRAS ranges from 0 to 12%[36],[37].